The effect of Selexipag on coagulation and fibrinolysis

JRCT ID: jRCT1021240025

Registered date:20/09/2024

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Chronic thromboembolic pulmonary hypetension
• Date of first enrollment: 09/09/2024
• Target sample size: 60
• Study type: Observational
• Intervention(s): nothing

Outcome(s)

Primary Outcome

Below assessment are performed before and after the treatment with Seloxipag.
Plasma clot lysis time, The score of coagulation or fibrinolysis as below: Plasminogen, PAI-1, Thrombin-Antithrombin, Thrombomodulin,TAFI

Secondary Outcome

cytokines chemokines: IL-1alpha, IL-1beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL15, IL-16, IL17, IL-18, IL-23, IL-1ra, IL-2Ralpha, Eotaxin, G-CSF, GM-CSF, IFN-ganma, KC, MCP-1, MIP-alpha, MIP-beta, TNF-alpha, TNF-beta, RANTES, FGF-basic, IP-10, GROa, HGF, IFN-alpha2, MCP-3, MIF, LIF, M-CSF, MIG, MIP-2, PDGF-BB, VEGF, TRAIL, CTACK, SDF-1aplha, b-NGF, SCF, SCGF-beta, P-selectin, PAC-1
Platelet function

Key inclusion & exclusion criteria

• Age minimum: >= 16age old
• Age maximum: Not applicable
• Include criteria: The patinet undertake the right heart catheterization to diagnose or treat chronic thromboembolic pulmonary hypertension
• Exclude criteria: Patients who are judged by the attending physician to be unsuitable for this study

Related Information

• Primary Sponsor: Yasuda Satoshi
• Source(s) of Monetary Support: Nippon Shinyaku